Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 9/20 | 1.00 |
| ▸ | ANPEP | P15144 | 2/20 | 0.62 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30011256 | 1.00 | FOLH1 (1.00) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| SCHEMBL5060653 | 0.87 | FOLH1 (0.75) | FOLH1ANPEPENPEP | |
| SCHEMBL4370854 | 0.84 | FOLH1 (0.72) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| SCHEMBL30791058 | 0.83 | FOLH1 (0.70) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| Benzoic Acid SCHEMBL28076089 | 0.83 | FOLH1 (0.70) | FOLH1ANPEPENPEPCA12CA1 | |
| SCHEMBL70351 | 0.83 | FOLH1 (0.70) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| SCHEMBL371526 | 0.83 | FOLH1 (0.70) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| SCHEMBL17058176 | 0.82 | FOLH1 (0.69) | FOLH1ANPEPENPEP | |
| SCHEMBL6081474 | 0.82 | FOLH1 (0.69) | FOLH1ANPEPENPEPCYP2D6CYP2C9 | |
| SCHEMBL1777321 | 0.81 | FOLH1 (0.68) | FOLH1ANPEPENPEPCYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110885532-A | High-bioactivity polyether-ether-ketone composite material artificial prosthesis and preparation method thereof | 常州华森医疗器械有限公司 | 2020-03-17 | — | — | CN | claimed |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | JUNTENDO EDUCATIONAL FOUNDATION (JP) | 2017-11-23 | — | — | US | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | claimed |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-4826888-A | STORAGE STABLE, DISCOLORATION INHIBITION | MITSUBISHI RAYON CO., LTD. (JP) | 1989-05-02 | — | — | US | claimed |
| US-12246000-B2 | Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides | VILNIUS UNIVERSITY (LT) | 2025-03-11 | — | — | US | disclosed |
| US-20240279845-A1 | METHOD FOR PREPARING A LIBRARY OF PEPTIDES OR A PEPTIDE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-08-22 | — | — | US | disclosed |
| CN-117897391-A | Method for preparing peptide library or peptide | 洛桑联邦政府综合工科学校（EPFL) | 2024-04-16 | — | — | CN | disclosed |
| EP-4341272-A1 | METHOD FOR PREPARING A LIBRARY OF PEPTIDES OR A PEPTIDE | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2024-03-27 | — | — | EP | disclosed |
| US-20240000736-A1 | INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES | VILNIUS UNIVERSITY (LT) | 2024-01-04 | — | — | US | disclosed |
| US-5631262-A | Pyridine compounds for treating leukotriene-related diseases | SMITHKLINE BEECHAM CORPORATION (US) | 1997-05-20 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| EP-0604529-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1994-07-06 | — | — | EP | disclosed |
| WO-1993006085-A1 | PYRIDINE COMPOUNDS FOR TREATING LEUKOTRIENE-RELATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279845-A1 | METHOD FOR PREPARING A LIBRARY OF PEPTIDES OR A PEPTIDE | VIP, PTMS, LANCL1 | FOLH1 825/4885ANPEP 25/4885ENPEP 23/4885 |
| US-20240000736-A1 | INHIBITION OF PROTEIN AMYLOID AGGREGATION USING FLUORINATED BENZENESULFONAMIDES | APP, APBA1, IAPP | FOLH1 3560/4885ANPEP 122/4885ENPEP 413/4885 |
| US-20170333516-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR AGE-RELATED MACULAR DEGENERATION | LTB4R, LTA4H, LTB4R2 | FOLH1 3795/4885ANPEP 4089/4885ENPEP 2468/4885 |
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | FOLH1 254/4885ANPEP 26/4885ENPEP 99/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | FOLH1 124/4885ANPEP 230/4885ENPEP 193/4885 |
| US-12246000-B2 | Inhibition of protein amyloid aggregation using fluorinated benzenesulfonamides | APP, APBA1, IAPP | FOLH1 3560/4885ANPEP 122/4885ENPEP 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.